AstraZeneca Results Presentation Deck

AstraZeneca in summary Pipeline-driven transformation Global presence Balanced specialty and primary-care franchises¹ Leading emerging markets presence with R&D base Strong pipeline 22 Phase III medicines and significant lifecycle projects Advancing early- and mid-stage pipeline Improving financials 1. In FY 2020, speciality-care medicines (Oncology, Brilinta, Lokelma, roxadustat and Fasenra) comprised 53% of total revenue 2. Cardiovascular, Renal & Metabolism and Respiratory & Immunology. 36 Eight blockbuster medicines Returned to durable revenue and earnings growth Focus on operating leverage and cash flow Innovative medicines in Oncology and BioPharmaceuticals² Experienced and proven team 4

View entire presentation